" /> Lifitegrast - CISMeF





Preferred Label : Lifitegrast;

NCIt related terms : Xiidra;

NCIt definition : A tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 (LFA-1) antagonist, that can be used as an ophthalmic solution for the treatment of dry eye disease (DED; keratoconjunctivitis sicca; dry eye syndrome). Upon ocular administration and although the exact mechanism of action of lifitegrast in DED is not fully known, lifitegrast targets and binds to the integrin LFA-1, a cell surface protein found on leukocytes. This prevents the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1). As ICAM-1 may be overexpressed in corneal and conjunctival tissues in DED, the blockage of the LFA-1/ICAM-1 interaction by lifitegrast may inhibit T-cell adhesion to ICAM-1 and may abrogate the formation of an immunological synapse. This may prevent T-cell proliferation, activation and migration and the release of pro-inflammatory cytokines in the corneal and conjunctival tissues. This may reduce inflammation, protect the corneal surface from inflammatory-mediated damage and reduce the symptoms of DED.;

UNII : 038E5L962W;

InChIKey : JFOZKMSJYSPYLN-QHCPKHFHSA-N;

CAS number : 1025967-78-5;

Drug name : Xiidra;

NCI Metathesaurus CUI : CL1413168;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
21/06/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.